A daily pill called daraxonrasib has shown significant potential in early clinical trials for treating advanced pancreatic cancer. When combined with chemotherapy, the drug caused tumours to become undetectable on scans in one in 12 patients, while growth was halted in nearly all of the 61 participants involved in the study. Experts from Cancer Research UK have described the development as the most significant advancement in the treatment of the disease in decades.
The medication functions as a targeted inhibitor that locks onto and deactivates RAS mutations, which are responsible for driving tumour growth in most pancreatic cancers. Dr. Wungki Park of the Memorial Sloan Kettering Cancer Center noted that the treatment has led to higher response rates and a near doubling in the duration of disease control. Researchers believe this could eventually translate into longer survival times for patients diagnosed with the condition.
Despite these encouraging results, medical professionals caution that the drug is not yet considered a cure and further long-term studies are required. It remains unclear how long the treatment can keep the disease in remission, as cancer can return even after scans show no signs of it. Because similar RAS mutations are found in other cancers, including lung and ovarian, scientists hope the success of this drug may eventually benefit a wider range of patients.

